Lupus

August 19, 2022

"Chronic cutaneous lupus erythematosus is prone to cause substantial disfigurement on visible skin, negatively impacting patients’ mental health and social life."

August 17, 2022

Although the role of PPIs in the occurrence of both drug-induced systemic lupus erythematosus and drug-induced cutaneous lupus erythematosus has been suggested, it remains poorly characterized.

August 11, 2022

"An unmet need is a biomarker that distinguishes active lupus nephritis, particularly important in pediatrics where minimizing invasive procedures is desirable.”

July 29, 2022

Although a third dose of mRNA vaccine significantly increased antireceptor-binding domain (RBD) titer in a previous study, clinical factors associated with the immunogenicity in immunosuppressed populations have not been adequately studied.

July 28, 2022

Despite advancements over the years, cutaneous lupus erythematosus (CLE) continues to represent a high unmet medical need with no cure.

July 27, 2022

The US FDA has approved belimumab for the treatment of active lupus nephritis in children aged 5 to 17 who are currently receiving standard therapy.

July 21, 2022

25% of patients presented with extensive blood-brain barrier leakage, which was linked to both cognitive impairment and shorter disease duration.

July 20, 2022

Previous assessments of the prevalence of lupus were conducted in short periods of time, therefore limiting the insight into long-term trends and potential explanations for the observed patterns.

July 18, 2022

As treatment options expand in SLE with an increasing number of targeted therapeutics, we can be optimistic about the potential to improve disease outcomes.

July 13, 2022

Additional doses improved seroconversion and most vaccinated patients with lupus experienced a generally mild course of the disease.